Scarica l'app Stockscreener
9.05
4.33%
-0.41
Pre-mercato:
9.04
-0.01
-0.11%
Precedente Chiudi:
$9.46
Aprire:
$9.17
Volume 24 ore:
90,205
Relative Volume:
0.78
Capitalizzazione di mercato:
$211.69M
Reddito:
-
Utile/perdita netta:
$-22.38M
Rapporto P/E:
-6.4184
EPS:
-1.41
Flusso di cassa netto:
$-15.54M
1 W Prestazione:
-6.22%
1M Prestazione:
+47.39%
6M Prestazione:
+46.92%
1 anno Prestazione:
+9.70%
Intervallo 1D:
$8.95
$9.68
Intervallo di 1 settimana:
$8.95
$10.71
Portata 52W:
$4.44
$11.80
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Nome
Nuvectis Pharma Inc
Settore
Industria
Telefono
360-837-7232
Indirizzo
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Confronta NVCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
9.05 | 211.69M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-02 | Iniziato | Maxim Group | Buy |
| 2025-03-17 | Iniziato | Laidlaw | Buy |
| 2022-07-13 | Iniziato | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Borsa (NVCT) Ultime notizie
Maxim Group Begins Coverage on Nuvectis Pharma (NASDAQ:NVCT) - Defense World
Maxim Group Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation - Nasdaq
Maxim Initiates Nuvectis Pharma at Buy With $17 Price Target - MarketScreener
Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (AACR) Conference - MarketScreener
(NVCT) Investment Analysis - news.stocktradersdaily.com
Nuvectis Pharma Announces Upcoming Presentations for NXP900 - GlobeNewswire
New Cancer Treatment Breakthrough: NXP900 Data Showcase at Major AACR Conference - Stock Titan
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Sees Large Decline in Short Interest - Defense World
Nuvectis Pharma (NASDAQ:NVCT) Now Covered by Analysts at Laidlaw - Defense World
Laidlaw & Co. Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation - Nasdaq
Laidlaw starts Nuvectis Pharma stock with Buy, $19 target By Investing.com - Investing.com Canada
Nuvectis Pharma initiated with a Buy at Laidlaw - TipRanks
Laidlaw starts Nuvectis Pharma stock with Buy, $19 target - Investing.com
(NVCT) Long Term Investment Analysis - news.stocktradersdaily.com
Nuvectis Pharma to Participate in the 37th Annual Roth Conference - GlobeNewswire
Nuvectis Pharma CEO Fireside Chat: Key Oncology Pipeline Updates Coming at Roth Conference - StockTitan
Oppenheimer & Co. Inc. Takes Position in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World
(NVCT) Proactive Strategies - Stock Traders Daily
Nuvectis announces new publication of research study on NXP900, osimertinib - TipRanks
Nuvectis reports promising cancer treatment results - Investing.com
Nuvectis reports promising cancer treatment results By Investing.com - Investing.com South Africa
Nuvectis Pharma Announces a New Publication of a Research - GlobeNewswire
Cleveland Clinic Study Confirms: Nuvectis Drug Makes Standard Lung Cancer Treatment More Effective - StockTitan
Roth Capital Forecasts Reduced Earnings for Nuvectis Pharma - Armenian Reporter
HC Wainwright Weighs in on Nuvectis Pharma Q1 Earnings - Defense World
Q1 EPS Estimates for Nuvectis Pharma Reduced by Roth Capital - Defense World
Nuvectis Pharma (NASDAQ:NVCT) Posts Quarterly Earnings Results, Misses Estimates By $0.08 EPS - MarketBeat
Nuvectis Pharma (NVCT) to Release Earnings on Tuesday - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Price Target Lowered to $11.00 at HC Wainwright - MarketBeat
FY2028 EPS Forecast for Nuvectis Pharma Reduced by Analyst - MarketBeat
FY2028 EPS Estimates for Nuvectis Pharma Reduced by Analyst - Defense World
Nuvectis Pharma Reports 2024 Financial Results and Progress - TipRanks
Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets - Marketscreener.com
HC Wainwright Lowers Nuvectis Pharma (NASDAQ:NVCT) Price Target to $11.00 - Defense World
Nuvectis Pharma Reports 2024 Financial Results and Updates on Oncology Pipeline - Defense World
Nuvectis Pharma initiated with a Buy at Lucid Capital - TipRanks
Optimistic Buy Rating for Nuvectis Pharma Driven by Promising Oncology Pipeline and Strong Financial Position - TipRanks
Nuvectis Pharma price target lowered to $11 from $21 at H.C. Wainwright - TipRanks
Nuvectis Pharma reports FY24 EPS ($1.11) vs. ($1.43) last year - TipRanks
Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights - The Manila Times
How Nuvectis Pharma Cut Losses by $3.3M While Pushing Forward Two Cancer Drug Candidates - StockTitan
Insiders Rewarded With US$915k Addition To Investment As Nuvectis Pharma Stock Hits US$185m - Simply Wall St
Nuvectis Pharma announces pricing of $13.5M public offering - MSN
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Purchases $1,200,000.00 in Stock - MarketBeat
Nuvectis pharma investor acquires $1.2 million in stock - MSN
(NVCT) Investment Analysis and Advice - Stock Traders Daily
Nuvectis Pharma Insider Bought Shares Worth $1,200,000, According to a Recent SEC Filing - Marketscreener.com
Major Investment Alert: Shareholder’s Big Move in Nuvectis Pharma! - TipRanks
Nuvectis pharma investor acquires $1.2 million in stock By Investing.com - Investing.com
Nuvectis Pharma prices 2.7M shares at $5.00 in underwritten public offering - MSN
Nuvectis Pharma Closes Stock Offering, Says Underwriter Exercised Overallotment Option - Marketscreener.com
Nuvectis Pharma Inc Azioni (NVCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):